Literature DB >> 6610439

Clinical and immunological study of non-Hodgkin T-cell lymphomas (cutaneous and lymphoblastic lymphomas excluded).

J C Brouet, C Rabian, C Gisselbrecht, G Flandrin.   

Abstract

We present here the immunologic, morphologic and clinical features of 16 T-derived adult non-Hodgkin lymphomas (NHL) (lymphoblastic and cutaneous lymphomas being excluded) observed in an unselected series of 260 NHL. Malignant cells bore T cell antigens (16 cases) but formed E rosettes in 14 cases only. In nine cases studied with monoclonal antibodies to T cell antigenic subsets, the phenotype of malignant cells was homogeneous; in seven cases the cells had a clear-cut helper or suppressor/cytotoxic phenotype; in one case cells had a cortical thymocyte phenotype. No T-cell subset antigens were detected on malignant cells from the last patient. Prominent morphologic features were a striking variation in tumour cell sizes, vascular proliferation and admixture of a large number of macrophages; most often, those lymphomas with a diffuse growth pattern could not be easily assigned to a given NHL subtype. The course of the disease was aggressive in most patients, only four having experienced a sustained complete remission. Waldeyer's ring involvement, waxing and waning nodes, polyclonal hypergammaglobulinaemia and skin infiltrates may be distinctive clinical features in some patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6610439     DOI: 10.1111/j.1365-2141.1984.tb02901.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  Histological, immunohistological and autopsy findings in lymphogranulomatosis X (including angio-immunoblastic lymphadenopathy).

Authors:  H Knecht; E W Schwarze; K Lennert
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

2.  HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma.

Authors:  T P Miller; S M Lippman; C M Spier; D J Slymen; T M Grogan
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.